Literature DB >> 4827061

Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions.

H Mars.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4827061     DOI: 10.1001/archneur.1974.00490360020005

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


× No keyword cloud information.
  5 in total

1.  Editorial: Dopa decarboxylase inhibitors.

Authors: 
Journal:  Br Med J       Date:  1974-11-02

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 3.  Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

4.  Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase.

Authors:  Anouke van Rumund; Lukas Pavelka; Rianne A J Esselink; Ben P M Geurtz; Ron A Wevers; Brit Mollenhauer; Rejko Krüger; Bastiaan R Bloem; Marcel M Verbeek
Journal:  NPJ Parkinsons Dis       Date:  2021-03-19

5.  Healthcare Professionals' Knowledge and Behaviors Regarding Drug-Dietary Supplement and Drug-Herbal Product Interactions.

Authors:  Zorica Stanojević-Ristić; Isidora Mrkić; Aleksandar Ćorac; Mirjana Dejanović; Radoslav Mitić; Leonida Vitković; Julijana Rašić; Dragana Valjarević; Aleksandar Valjarević
Journal:  Int J Environ Res Public Health       Date:  2022-04-03       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.